Omniscient has been highly successful in obtaining Federal research funding to drive its progress, along with seed round investments. Since 2016, we have received Phase I and Phase II STTR awards, and recently received an SBIR Fast Track award from the National Cancer Institure (NIH). Continuing funding from the NIH validates our technology and commercialization plan. As the company advances, it will look to individual/ institutional investors and corporate partners to drive further growth.
News
November 2023 | Fully functioning endoseer prototype completed
May 2022 | First in-vivo results from optical prototype for omni-directional imaging presented at Digestive Diseases Week, San Diego, CA
August 2019 | Fast track SBIR award from National Cancer Institute (NIH) awarded
May 2019 | Test results from second optical prototype presented at Digestive Diseases Week, San Diego, CA
September 2018 | STTR Phase II award received from National Cancer Institute (NIH) awarded
November 2018 | Omniscient featured in Med Tech Strategist as a ‘Startup to Watch’ November 2018
April 2017 | Dr. Banerjee interviewed by AZ Public Media / NPR
May 2016 | STTR Phase I award from National Cancer Institute/NIH
May 2015 | Test results from 1st prototype presented at Digestive Diseases Week, Washington, DC
February 2015 | Presentation at SPIE BiOS, San Francisco, CA